Related Experiment Video
Updated: Sep 2, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
The Burden of Prior Authorizations in Bleeding Disorder Specialty Drugs
Lisa Littner1,2, Jami Jones3, Trudie Milner3
1Medical University of South Carolina, Charleston, South Carolina, USA.
Introduction:
Prior authorizations (PAs) are widely used to control healthcare costs and ensure appropriate use of high-cost therapies, but they often create undue administrative burdens. In haemophilia care, timely access to specialty medications is critical, yet Haemophilia Treatment Centres (HTCs) must frequently navigate payer-driven PA requirements that can delay treatment and disrupt care delivery. To our knowledge, this study is the first of its kind to examine how the PA process affects patient care and provider workloads in HTCs METHODS: Twenty staff from federally designated HTCs across the United States were purposively recruited to participate in virtual, semi-structured interviews. Eligible participants were directly involved in the PA process. Interviews were recorded, transcribed, and de-identified. Data were analyzed using conventional content analysis with independent coding by two investigators, supported by Dedoose software. Descriptive statistics summarized participant characteristics, and the labour-time and cost estimate was estimated by annualizing labour costs using mean weekly hours spent on PAs and position-specific wage rates.
Results:
A thematic analysis revealed four themes related to PA challenges and the burden on care delivery. The mean weekly time spent on PAs was 6.5 h per participant. Eighty-five percent of participants reported burnout related to PAs. The labour-time and cost estimate per participant-year spent on PAs ranged from $4795 (nurse practitioner) to $20,718 (non-clinical staff).
Conclusion:
The findings emphasize the need for efficient, clinically informed PA processes to reduce administrative burden and care delays, and identify a need for further education for insurers, potentially at the national level.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Products: Biologics, Biosimilars and Interchangeables